Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_FF6C3BE61AB1
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Institution
UNIL/CHUV
Titre
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Périodique
Targeted oncology
Auteur⸱e⸱s
Faivre S., de Gramont A., Raymond E.
ISSN
1776-260X (Electronic)
ISSN-L
1776-2596
Statut éditorial
Publié
Date de publication
08/2016
Peer-reviewed
Oui
Volume
11
Numéro
4
Pages
565-567
Langue
anglais
Notes
Publication types: Letter
Publication Status: ppublish
Mots-clé
Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Carcinoma, Hepatocellular/drug therapy, Clinical Trials, Phase III as Topic, Humans, Liver Neoplasms/drug therapy, Niacinamide/adverse effects, Niacinamide/analogs & derivatives, Niacinamide/therapeutic use, Phenylurea Compounds/adverse effects, Phenylurea Compounds/therapeutic use, Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/therapeutic use, Randomized Controlled Trials as Topic
OAI-PMH
oai:serval.unil.ch:BIB_FF6C3BE61AB1
DOI
10.1007/s11523-016-0427-8
Pubmed
26996978
Création de la notice
01/04/2016 11:46
Dernière modification de la notice
21/08/2019 6:16
Données d'usage